# Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

> **NCT04260009** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumors
- Solid Tumors

## Interventions

- **DRUG:** Brigatinib
- **DRUG:** Brigatinib AAF

## Key facts

- **NCT ID:** NCT04260009
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reason unrelated to product safety
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260009, "Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04260009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*